No Data
PXI Research Memo (10): After achieving the elimination of accumulated losses and establishing a stable financial structure, the policy of shareholder returns will be implemented.
Regarding shareholder returns, we have recorded cumulative losses since our founding. Currently, we are in a stage of establishing our business through research and development and capital investment, therefore we have not implemented profit dividends.
PXG Research Memo (9): Expanding product sales and more for the high-growth next-generation pharmaceutical market.
Phoenix Bio's growth strategy 2. Against the backdrop of expanding markets for next-generation pharmaceuticals, including growth nucleic acid pharmaceuticals, and expanding demand for liver cells, the company has set a growth strategy to expand sales of its products (PXB mouse, PXB-cells related products) and outsourcing safety testing services in the high-growth next-generation pharmaceuticals market. Regarding PXB mouse, the company plans to expand sales channels and production facilities in Japan and North America in response to increased demand.
PX Research Memo (8): The market environment is favorable.
Phoenix Bio's growth strategy: 1. Market environment Pharmaceutical development is shifting to the next-generation pharmaceuticals (nucleic acid drugs, cell therapy/regenerative medicine, etc.), which are more effective and safer, targeting not only low-molecular-weight drugs and antibody drugs targeting "proteins" that cause diseases, but also the synthesis of "proteins" that cause diseases by targeting human "DNA" and "RNA". This trend is based on drug discovery modalities (drug development
Financial estimates show significant growth in revenue and profit for the March 2025 fiscal year in PXB's Research Memo (7).
Future Outlook: Overview of Financial Estimates for FY 2025 Phoenixbio <6190>'s consolidated revenue for the fiscal year ended March 2025 is expected to increase significantly, with revenues of 2,121 million yen, up 23.7% from the previous year, operating profit of 214 million yen (11 million yen in the previous year), ordinary profit of 214 million yen, up 393.6% from the previous year, and net income attributable to shareholders of the parent company of 201 million yen, up 662.3% from the previous year, all attributed to the significant gains from new drug development using new modalities such as nucleic acid pharmaceuticals and gene therapy.
PXB Research Memo (5): Pharmaceutical companies' investment in new drug development is a risk factor.
Overview of Phoenix Bio <6190> Business 4. Risk factors and challenges/countermeasures Risk factors include trends in investment in new drug development by pharmaceutical companies and research institutions, trends in competition, and legal regulations. With regard to trends in investment in new drug development by pharmaceutical companies and research institutions, the discontinuation of the development of anti-hepatitis B virus drugs by overseas pharmaceutical companies has resulted in a significant decline in revenue from contract testing services, and the risk has become apparent. In response to this, the company is engaged in activities related to anti-hepatitis B virus drugs.
PXG Research Memo (4): Shift in strategy toward product sales, orders are bottoming out in the March 2023 period and on a recovery trend.
Phoenix Bio's business overview: 3. Revenue by field and service line In the 2024 fiscal year ending in March, revenue from the pharmacology and pharmacology field was 159 million yen, while revenue from the safety and other areas was 1,556 million yen. Revenue by service line was 1,320 million yen from product sales and 396 million yen from contract testing services. The number of customers in the safety and other areas decreased by 3 companies compared to the previous period to 38 companies overseas and by 7 companies to 59 companies domestically. In the fiscal year ending in March 2024, Alnylam was the main sales destination.
No Data
No Data